新闻
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China

北京市医保新增513种报销药品 包括15种抗癌靶向药

2017-08-31 15:46:06   国际在线

针对定点医疗机构中提供医保服务的医师,通过“大数据”综合分析医师的诊疗行为,筛选出不合理诊疗用药导致医保基金浪费的医师名单,情节严重的,可停止其开具处方的费用报销,打击“大处方”“滥开药”。

  配套措施

  门诊特殊病种扩至11种 一年为患者减负3.5亿元

9月1日起,北京市同步调整门诊特殊病病种,扩至11种,仅此一项每年就将为大病患者减负约3.5亿元。

同步调整门诊特殊病种

2001年起,本市建立“门诊特殊疾病”制度,部分需要长期门诊治疗、费用较高的大病患者,其门诊治疗的相关费用,按照住院报销比例和报销限额执行,且360天内只收取一个起付线。目前,本市规定的门诊特殊病范围已达9种,分别是恶性肿瘤放射治疗和化学治疗、肾透析、肾移植术后抗排异治疗、血友病、再生障碍性贫血、肝移植术后抗排异治疗、肝肾联合移植术后抗排异治疗、心脏移植术后抗排异治疗、肺移植术后抗排异治疗。

为使此次纳入报销范围的36种谈判药品更好的服务于重病患者,9月1日起,本市同步调整门诊特殊病病种范围,将现有门诊特殊病“恶性肿瘤放射治疗和化学治疗”调整为“恶性肿瘤门诊治疗”,同时新增“多发性硬化”和“黄斑变性眼内注射治疗”,至此,本市门诊特殊病病种达11种。

几字之差大幅减负

有关负责人介绍,从“恶性肿瘤放射治疗和化学治疗”到“恶性肿瘤门诊治疗”,几字之差,扩大了此类患者的门诊治疗范围,调整后,恶性肿瘤患者的门诊治疗,将在现有放化疗用药报销范围的基础上,新增加42种药品,其中包含15种靶向治疗药品和国家新增品种中的相关药品。

以退休人员为例,治疗乳腺癌的靶向药“曲妥珠单抗(赫赛汀)”,国家谈判前,年均药品费用约23万元,全部自费;谈判后年均药品费用约9万元,纳入门诊特殊病报销后个人每年负担约为1万元。治疗“多发性硬化”的靶向药“重组人干扰素β-1b(倍泰龙)”,国家谈判前,年均药品费用个人负担近15万元;谈判后年均药品费用约10.6万元,纳入门诊特殊病报销后退休人员个人负担约为1.2万元,大大减轻患者的医疗费用负担。

据测算,此次门诊特殊病政策调整后,每年将为大病患者减轻医疗费用负担约3.5亿元。

门诊特殊病审批变备案

自去年11月起,本市简化门诊特殊病审批流程,由“审批”变“备案”。患门诊特殊病的参保人员可以直接在所选的特殊病定点医院填写申报表,由医师签字后,持社保卡到医院医保办公室办理备案手续,实现申报、备案、待遇查询及治疗等手续“一站式”完成,无需再到单位、经办机构办理,大大减轻患者及家属往返奔波之苦。

对于异地安置或长期派驻外地工作人员,患门诊特殊病选择异地定点医院时,可持社保卡、诊断证明及申报表到参保区医保经办机构办理备案手续。

目前,本市已有近5.4万门诊特殊病患者按简化流程进行申报。(记者 袁京)

(原标题:医保新增513种可报销药品)

上一页2/2下一页
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China

相关阅读

404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China
分享到:
0 0
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China

美图推荐

404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China

为您推荐

加载更多>>
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China
404 Not Found

404 Not Found

Sorry for the inconvenience.
Please report this message and include the following information to us.
Thank you very much!

URL: http://3g.china.com:8080/act/news/11038989/20170831/31244541_2.html
Server: cms-8-252
Date: 2024/12/02 21:21:31

Powered by China
China